These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 34003553)

  • 21. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
    Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
    Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting ASCT2-mediated glutamine metabolism inhibits proliferation and promotes apoptosis of pancreatic cancer cells.
    Wang W; Pan H; Ren F; Chen H; Ren P
    Biosci Rep; 2022 Mar; 42(3):. PubMed ID: 35237783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLC38A2 Overexpression Induces a Cancer-like Metabolic Profile and Cooperates with SLC1A5 in Pan-cancer Prognosis.
    Huang MS; Chang JH; Lin WC; Cheng YH; Li FA; Suen CS; Hwang MJ; Chang CK; Mou KY
    Chem Asian J; 2020 Nov; 15(22):3861-3872. PubMed ID: 32996252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual role of sprouty2 as an inhibitor of RAS/ERK-driven proliferation and a promoter of cancer invasion in KRAS wild-type colorectal cancer.
    Lee CT; Chu CA; Wang YM; Wang YW; Chen YL; Ho CL; Yeh YM; Lin PC; Lin BW; Chen PC; Chen SH; Chan RH; Chang C; Chow NH
    Mol Carcinog; 2023 Jul; 62(7):951-962. PubMed ID: 37014154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SLC25A21 downregulation promotes KRAS-mutant colorectal cancer progression by increasing glutamine anaplerosis.
    Hu SS; Han Y; Tan TY; Chen H; Gao JW; Wang L; Yang MH; Zhao L; Wang YQ; Ding YQ; Wang S
    JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
    Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
    Wang L; Liu Y; Zhao TL; Li ZZ; He JY; Zhang BJ; Du HZ; Jiang JW; Yuan ST; Sun L
    Phytomedicine; 2019 Apr; 57():117-128. PubMed ID: 30668314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
    Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
    Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.
    White MA; Lin C; Rajapakshe K; Dong J; Shi Y; Tsouko E; Mukhopadhyay R; Jasso D; Dawood W; Coarfa C; Frigo DE
    Mol Cancer Res; 2017 Aug; 15(8):1017-1028. PubMed ID: 28507054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of Amino Acid Homeostasis by Novel ASCT2 Inhibitors Involves Multiple Targets.
    Bröer A; Fairweather S; Bröer S
    Front Pharmacol; 2018; 9():785. PubMed ID: 30072900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesothelioma cancer cells are glutamine addicted and glutamine restriction reduces YAP1 signaling to attenuate tumor formation.
    Adhikary G; Shrestha S; Naselsky W; Newland JJ; Chen X; Xu W; Emadi A; Friedberg JS; Eckert RL
    Mol Carcinog; 2023 Apr; 62(4):438-449. PubMed ID: 36562471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Variant of SLC1A5 Is a Mitochondrial Glutamine Transporter for Metabolic Reprogramming in Cancer Cells.
    Yoo HC; Park SJ; Nam M; Kang J; Kim K; Yeo JH; Kim JK; Heo Y; Lee HS; Lee MY; Lee CW; Kang JS; Kim YH; Lee J; Choi J; Hwang GS; Bang S; Han JM
    Cell Metab; 2020 Feb; 31(2):267-283.e12. PubMed ID: 31866442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical role of ASCT2-mediated amino acid metabolism in promoting leukaemia development and progression.
    Ni F; Yu WM; Li Z; Graham DK; Jin L; Kang S; Rossi MR; Li S; Broxmeyer HE; Qu CK
    Nat Metab; 2019 Mar; 1(3):390-403. PubMed ID: 31535081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2.
    Okudaira H; Nakanishi T; Oka S; Kobayashi M; Tamagami H; Schuster DM; Goodman MM; Shirakami Y; Tamai I; Kawai K
    Nucl Med Biol; 2013 Jul; 40(5):670-5. PubMed ID: 23647854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TFEB controls retromer expression in response to nutrient availability.
    Curnock R; Calcagni A; Ballabio A; Cullen PJ
    J Cell Biol; 2019 Dec; 218(12):3954-3966. PubMed ID: 31694921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amino acids regulate mTOR pathway and milk protein synthesis in a mouse mammary epithelial cell line is partly mediated by T1R1/T1R3.
    Wang Y; Liu J; Wu H; Fang X; Chen H; Zhang C
    Eur J Nutr; 2017 Dec; 56(8):2467-2474. PubMed ID: 27539583
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
    Wang Z; Kang B; Gao Q; Huang L; Di J; Fan Y; Yu J; Jiang B; Gao F; Wang D; Sun H; Gu Y; Li J; Su X
    Cancer Sci; 2021 Sep; 112(9):3895-3910. PubMed ID: 34185934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
    Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
    Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI assessment of glutamine uptake correlates with the distribution of glutamine transporters and cancer stem cell markers.
    Seo Y; Kang J; Kim TI; Joo CG
    Sci Rep; 2022 Apr; 12(1):5511. PubMed ID: 35365739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
    Wu K; Wu B; Yan K; Ding Q; Miao Z
    Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.